Idenix raises over $100M from Baupost

Idenix Pharmaceuticals (IDIX) has received a net $106.7M by selling 16.42M shares to the The Baupost Group at $6.50 each vs Idenix's close of $6.87 yesterday.

With the deal, Baupost increases its holdings to 35% from 27%.

Idenix will use the money for clinical trials and patent litigation. The company estimates that it will now have funding until H2 2015. (PR)

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs